Physiological elevations of plasma free fatty acids (FFA) have been shown to produce insulin resistance dose-dependently in healthy and in diabetic subjects and to increase insulin secretion chronically in healthy subjects. However, FFA stimulated insulin secretion less in diabetic (NIDDM) than in non-diabetic subjects. These findings suggested that in most obese subjects, FFA increased insulin secretion sufficiently to compensate for the insulin resistance that they had generated and thus prevented deterioration of glucose tolerance. The objective of the current project is to determine the reason why a minority of obese subjects develop diabetes (NIDDM). Specifically, we plan to test the hypothesis 1) that in obese subjects, who are genetically predisposed to develop NIDDM, FFA fail to appropriate stimulate insulin secretion and 2) that this would then leave peripheral and hepatic insulin resistance, at least partially, uncompensated, resulting in NIDDM. To test this hypothesis, we propose to study effects of a wide spectrum of a wide plasma FFA concentrations on insulin secretions in 3 groups of subjects, representing 3 stages in the development of NIDDM. The 3 groups will consist of 1) first degree relatives of patients with NIDDM. These subjects are normally glucose tolerant, but are considered to be at high risk to develop NIDDM; 2) subjects who have impaired glucose tolerance, i.e., individuals in whom glucose tolerance has not yet deteriorated to the point of frank diabetes and 3) patients with newly diagnosed NIDDM (< 1 year). In all subjects, plasma FFA levels will be either lowered (with nicotinic acid, Test 1) or maintained at basal levels (with saline plus glycerol, Test 2) or increased (with IV lipid plus heparin, Test 3). Plasma glucose concentrations will be clamped at euglycemic levels (all subjects). To assess hepatic actions FFA in more detail we will test effects of elevated plasma FFA (IV lipid/heparin) on rates of gluconeogenesis and glycogenolysis in patients with NIDDM and controls. NIDDM affects between 20 and 30% of the elderly population in the US and is responsible for a large amount of morbidity and mortality. We hope that this project will help to better understand the mechanisms by which obesity contributes to the development of NIDDM.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG015363-02
Application #
6124244
Study Section
Metabolism Study Section (MET)
Program Officer
Premen, Andre J
Project Start
1998-12-01
Project End
2003-11-30
Budget Start
1999-12-01
Budget End
2000-11-30
Support Year
2
Fiscal Year
2000
Total Cost
$240,504
Indirect Cost
Name
Temple University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Boden, Guenther (2004) Gluconeogenesis and glycogenolysis in health and diabetes. J Investig Med 52:375-8
Homko, Carol; Deluzio, Antonio; Jimenez, Carolyn et al. (2003) Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care 26:2027-31
Boden, Guenther (2003) Effects of free fatty acids on gluconeogenesis and glycogenolysis. Life Sci 72:977-88
Boden, G (2003) Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes 111:121-4
Cheung, Peter; Yang, Gangyi; Boden, Guenther (2003) Milrinone, a selective phosphodiesterase 3 inhibitor, stimulates lipolysis, endogenous glucose production, and insulin secretion. Metabolism 52:1496-500
Sivan, Eyal; Boden, Guenther (2003) Free fatty acids, insulin resistance, and pregnancy. Curr Diab Rep 3:319-22
Boden, Guenther (2002) Interaction between free fatty acids and glucose metabolism. Curr Opin Clin Nutr Metab Care 5:545-9
Boden, G (2001) Pathogenesis of type 2 diabetes. Insulin resistance. Endocrinol Metab Clin North Am 30:801-15, v
Homko, C; Sivan, E; Chen, X et al. (2001) Insulin secretion during and after pregnancy in patients with gestational diabetes mellitus. J Clin Endocrinol Metab 86:568-73
Boden, G; Chen, X; Polansky, M (1999) Disruption of circadian insulin secretion is associated with reduced glucose uptake in first-degree relatives of patients with type 2 diabetes. Diabetes 48:2182-8